Last reviewed · How we verify
Test formulation (Treatment D) (test-formulation-treatment-d)
Test formulation (Treatment D) (generic name: test-formulation-treatment-d) is a Small molecule drug developed by Pfizer Inc.. It is currently in Phase 1 development.
A study (NCT02031666) was conducted to assess the relative bioavailability of 7 test tablet formulations of JNJ-56021927 compared to the capsule formulation. The study involved administering JNJ-56021927 in various forms, including capsules and tablets, to healthy participants.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | test-formulation-treatment-d |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Postural orthostatic tachycardia syndrome
- Dizziness
- catheter site
- toothache
- Constipation
- diarrhea
- nasopharyngitis
- visual impairment
- pigmentation disorder
- presyncope
- somnolence
Key clinical trials
- A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults (PHASE1)
- Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (PHASE1, PHASE2)
- A Phase 1 Study of FZ008-145 in Healthy Subjects. (PHASE1)
- Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers (PHASE1)
- A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults (PHASE1)
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State. (PHASE1)
- A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) (PHASE1)
- A Study in Healthy People to Test How 3 Different Formulations of BI 764198 Are Taken up in the Body and How This is Influenced by Food (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test formulation (Treatment D) CI brief — competitive landscape report
- Test formulation (Treatment D) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Test formulation (Treatment D)
What is Test formulation (Treatment D)?
Who makes Test formulation (Treatment D)?
What is the generic name of Test formulation (Treatment D)?
What development phase is Test formulation (Treatment D) in?
What are the side effects of Test formulation (Treatment D)?
Related
- Manufacturer: Pfizer Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing